Bharat Rasayan Ltd Valuation Shifts: From Attractive to Fair Amidst Market Volatility

Valuation Metrics and Recent Changes

As of 1 February 2026, Bharat Rasayan’s price-to-earnings (P/E) ratio stands at 21.53, a figure that has contributed to its reclassification from an attractive to a fair valuation grade. This P/E multiple, while moderate, is notably lower than several peers in the pesticides and agrochemicals industry, such as Bayer CropScience with a P/E of 33.07 and BASF India at 41.41. However, it is higher than Sharda Cropchem’s 16.58 and Dhanuka Agritech’s 17.06, companies currently rated as attractive or very attractive on valuation grounds.

The price-to-book value (P/BV) ratio for Bharat Rasayan is 2.59, which aligns with a fair valuation stance, indicating that the stock is neither undervalued nor excessively priced relative to its book value. This contrasts with some peers like Anupam Rasayan, which trades at a very expensive P/E of 93.67 and a correspondingly high P/BV, signalling a premium valuation driven by growth expectations.

Enterprise value to EBITDA (EV/EBITDA) for Bharat Rasayan is 15.48, again placing it in the fair valuation category. This multiple is considerably lower than Bhagiradha Chemicals’ EV/EBITDA of 74.4, which is classified as very expensive, but higher than Sharda Cropchem’s 9.64, which remains attractive. The EV to EBIT ratio of 18.08 further supports the notion that Bharat Rasayan’s valuation is balanced but lacks the compelling discount that might attract value-focused investors.

Financial Performance and Returns Context

From a profitability standpoint, Bharat Rasayan’s return on capital employed (ROCE) is a healthy 15.98%, while return on equity (ROE) stands at 12.04%. These figures indicate efficient capital utilisation and reasonable shareholder returns, though they do not markedly outpace sector averages to justify a premium valuation.

Dividend yield remains minimal at 0.02%, suggesting that the company prioritises reinvestment or growth over shareholder payouts, a factor that may influence valuation perceptions among income-focused investors.

Examining stock price performance relative to the broader market, Bharat Rasayan has delivered a remarkable 639.19% return over the past decade, significantly outperforming the Sensex’s 230.79% gain. However, more recent performance has been lacklustre, with a 25.36% decline over the last year compared to a 7.18% gain in the Sensex. Year-to-date and one-month returns also reflect underperformance, with losses of approximately 16% versus Sensex declines of around 3%. This recent weakness has likely contributed to the tempered valuation outlook.

Comparative Valuation Analysis Within the Sector

When benchmarked against its peers, Bharat Rasayan’s valuation appears moderate but less compelling. Bayer CropScience and BASF India, despite their higher multiples, command premium valuations due to their global scale and diversified product portfolios. Conversely, companies like Sharda Cropchem and Dhanuka Agritech offer more attractive valuations with lower P/E and EV/EBITDA multiples, reflecting either higher growth potential or market scepticism about their risk profiles.

Notably, some peers such as Anupam Rasayan and Bhagiradha Chemicals trade at very expensive valuations, with P/E ratios exceeding 90 and 225 respectively, signalling strong growth expectations but also elevated risk. Bharat Rasayan’s fair valuation grade suggests a more cautious market stance, possibly due to recent stock price volatility and sector headwinds.

Market Capitalisation and Quality Grades

Bharat Rasayan holds a market capitalisation grade of 3, indicating a mid-tier size within its sector. Its Mojo Score has deteriorated to 26.0, with a recent downgrade from Sell to Strong Sell on 6 January 2026. This downgrade reflects concerns over valuation, earnings momentum, and relative price performance, signalling caution to investors.

The company’s PEG ratio remains at 0.00, which may indicate either a lack of meaningful earnings growth projections or data unavailability. This contrasts with peers like Bayer CropScience, which has a PEG of 6.54, reflecting high growth expectations priced into the stock.

Price Movement and Trading Range

On 1 February 2026, Bharat Rasayan’s stock price closed at ₹1,866.45, up 7.73% from the previous close of ₹1,732.55. The day’s trading range was ₹1,692.70 to ₹1,877.40, indicating intraday volatility. The stock remains well below its 52-week high of ₹3,030.25 but above its 52-week low of ₹1,537.45, reflecting a wide trading band over the past year.

Implications for Investors

The shift in Bharat Rasayan’s valuation grade from attractive to fair signals a more cautious stance for investors considering exposure to this stock. While the company maintains solid fundamentals with respectable ROCE and ROE figures, its recent price underperformance relative to the Sensex and peers has tempered enthusiasm.

Investors should weigh the company’s moderate valuation multiples against its growth prospects and sector dynamics. The pesticides and agrochemicals industry is subject to regulatory changes, commodity price fluctuations, and evolving demand patterns, all of which can impact earnings visibility and valuation premiums.

Given the downgrade to a Strong Sell Mojo Grade and the fair valuation status, investors may prefer to monitor the stock for signs of stabilisation or improvement in earnings momentum before committing fresh capital. Alternatively, exploring more attractively valued peers with stronger growth trajectories or more favourable risk profiles could be prudent.

Historical Performance Versus Market Benchmarks

Over the long term, Bharat Rasayan has delivered exceptional returns, with a 10-year stock return of 639.19%, far outpacing the Sensex’s 230.79% gain. However, the recent five-year and three-year returns of -25.15% and -19.29% respectively highlight a significant slowdown and correction phase. This divergence underscores the importance of valuation discipline and timing in capital allocation decisions.

Shorter-term returns also reflect volatility, with a 1-week gain of 19.18% contrasting sharply with 1-month and year-to-date declines exceeding 16%. Such fluctuations may be driven by sector-specific news, earnings announcements, or broader market sentiment shifts.

Conclusion

Bharat Rasayan Ltd’s transition from an attractive to a fair valuation grade encapsulates the evolving market assessment of its price attractiveness amid sector competition and recent performance challenges. While the company’s fundamentals remain sound, the tempered valuation multiples and recent Mojo Grade downgrade suggest investors should exercise caution and consider alternative opportunities within the pesticides and agrochemicals space.

Careful monitoring of earnings trends, sector developments, and peer valuations will be essential for investors seeking to navigate this complex landscape. Bharat Rasayan’s current valuation offers neither a compelling discount nor a premium growth story, positioning it as a stock for selective consideration rather than aggressive accumulation at present.

Unlock special upgrade rates for a limited period. Start Saving Now →